<DOC>
	<DOCNO>NCT01098357</DOCNO>
	<brief_summary>This open-label , active-control , multicentre , parallel group , randomise dose-finding efficacy safety study . Compare efficacy safety BioChaperone PDGF-BB apply 12.5 µg/cm² every two day 20 week becaplermin gel ( Regranex® Gel 0.01 % ) apply daily 20 week treatment neuropathic diabetic foot ulcer . Assess effect double dose BioChaperone PDGF-BB ( 25 µg/cm² ) apply every two day 20 week .</brief_summary>
	<brief_title>Comparative Study 3 Dose Regimens BioChaperone Becaplermin Gel Treatment Diabetic Foot Ulcer</brief_title>
	<detailed_description>After screen visit , eligible patient population randomly receive one three follow topical drug : - BioChaperone™ PDGF-BB 12.5 µg/cm²/application 20 week , - BioChaperone™ PDGF-BB 25 µg/cm²/application 20 week , - BioChaperone™ PDGF-BB 4 µg/cm²/application 20 week , - Beclapermin gel 6.25 µg/cm²/application 20 week . The assessment schedule four group weekly ( 7 day duration ) till 8th week ( visit 10 ) two week ( 14 day duration ) thereafter till end study . The maximum number visit expect 16 . The study data present end 20 week .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<criteria>Men woman age 18 year old old , type 1 2 diabetes mellitus . Single fullthickness plantar ulcer extremity ( malleolus ) extend epidermis dermis , involve bone , tendon , ligament muscle ( grade IA define University Texas Diabetic Wound Classification ) . Chronic ulcer least six week despite appropriate wound care . Ulcer area ( great length great width ) , follow sharp debridement , 1 10 cm² , inclusive . Well control infection cellulitis ( systemic antibiotherapy ) . Peripheral neuropathy assess SemmesWeinstein monofilament test bio esthesimeter ( vibration perception threshold ) . Adequate arterial blood supply , measure ( color ) doppler ultrasonography , ankle brachial pressure index &gt; 0.60 , ankle systolic pressure &gt; 70 mmHg toe pressure &gt; 30 mmHg . Ankle brachial pressure index lower 1.3 ( frequently relate medial artery calcification . Women surgically sterile , postmenopausal , agree practice adequate contraception negative pregnancy test screening . Nonnursing . Signed informed consent study procedure . Ulcer cause origin : electrical , chemical radiation insult , bedsore , vascular ulcer Charcot deformities ulcer . Active ulcer infection assess clinical examination radiographic necessary . Presence necrosis , purulence sinus tracts remove debridement . Active osteomyelitis affect area target ulcer . Poorly control diabetes ( uncontrolled glycemia : HbA1c ≥ 12 % ) , renal failure ( serum creatinine &gt; 3.0 mg/dL ) , poor nutritional status ( albumin &lt; 3.0 g/dL total protein &lt; 6.5 g/dL ) . Known connective tissue malignant disease . Concomitant treatment corticosteroid , immunosuppressive agent , radiation therapy , anticancer chemotherapy . Use investigational drug/device within 30 day . Topical application advance wound care wound ( Growth Factor , antiseptic , antibiotic debriders ) within 7 day . Vascular reconstruction within 8 week . Patients expect noncompliant protocol ( available duration trial , treatment wound care compliance ) , felt unsuitable Investigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>rhPDGF , diabetic foot ulcer ,</keyword>
</DOC>